



**Liver Cancer Conference**  
**October 30, 2021**  
**Virtual Program**

At course completion, attendees should be able to: Increase Knowledge Understand the molecular classification of HCC Understand the multidisciplinary approach to management of HCC Competency Define the mechanisms that lead to the development of hepatocellular cancer (HCC) Performance Discuss the available evidence-based data on promising treatment options for advanced HCC Discuss the advances in research and development

**Target Audience**

*This program is directed to providers, patients and caregivers. Concurrent educational sessions will be held for hepatologists, gastroenterologists, oncologists, primary care physicians and other health care providers involved in the management of patients with liver cancer. A separate session will be geared towards patients and their caregivers.*

**Program Overview**

The goal of this course module is to help clinicians and other service providers understand the management of Hepatocellular Carcinoma in the US population, innovations in therapies and advances in research and development.

**Learning Objectives**

At course completion, attendees should be able to:

**Increase Knowledge**

Understand the molecular classification of HCC  
Understand the multidisciplinary approach to management of HCC

**Competency**

Define the mechanisms that lead to the development of hepatocellular cancer (HCC)

**Performance**

Discuss the available evidence-based data on promising treatment options for advanced HCC  
Discuss the advances in research and development

**Course Directors**

Dulabh K. Monga, MD  
Program Director  
Hematology Oncology Fellowship  
Assistant Professor of Medicine  
Temple University School of Medicine  
Allegheny Health Network  
Pittsburgh, PA

Satdarshan (Paul) Singh Monga, MD  
UPMC Endowed Chair for Experimental Pathology  
Professor of Pathology and Medicine  
Director, Pittsburgh Liver Research Center,  
Chief and Vice Chair, Division of Experimental Pathology  
University of Pittsburgh, School of Medicine and UPMC  
Pittsburgh, PA

## **Faculty Listing**

Dulabh K. Monga, MD  
Program Director  
Hematology Oncology Fellowship  
Assistant Professor of Medicine  
Temple University School of Medicine  
Allegheny Health Network  
Pittsburgh, PA

Satdarshan (Paul) Singh Monga, MD  
UPMC Endowed Chair for Experimental Pathology  
Professor of Pathology and Medicine  
Director, Pittsburgh Liver Research Center,  
Chief and Vice Chair, Division of Experimental Pathology  
University of Pittsburgh, School of Medicine and UPMC  
Pittsburgh, PA

David Geller, MD  
Director  
UPMC Liver Cancer Center  
Pittsburgh, PA

Andrew Klobuka, MD  
Department of Radiology  
Allegheny Health Network  
Pittsburgh, PA

Brittany Morocco, PA-C  
Senior Physician Assistant  
UPMC Liver Cancer Center  
Pittsburgh, PA

Suzanna Masartis,  
CEO  
Community Liver Alliance  
Pittsburgh, PA

Paul Renz, DO  
Radiotherapy Therapy for Hepatocellular Carcinoma  
Allegheny Health Network  
Pittsburgh, PA

Mitesh Borad, MD  
Associate Professor of Medicine Consultant, Division of Hematology/Oncology, Department of Internal  
Medicine  
Consultant, Department of Molecular Medicine  
Mayo Clinic  
Scottsdale, AZ

Obaid Shaikh, MD  
Director, Transplant Medicine  
Professor, Division of Gastroenterology, Hepatology and Nutrition  
UPMC

## Schedule

### **8:15-8:30 a.m. Welcome and Overview**

Dulabh K Monga, MD and Satdarshan (Paul) Monga, MD  
Course Directors

Suzanna Masartis  
CEO, Community Liver Alliance

### **8:30-9:00 a.m. How Does Liver Cancer Develop?**

Satdarshan (Paul) Monga, MD  
Professor and Vice Chair of Pathology  
Director, Pittsburgh Liver Research Center,  
University of Pittsburgh and UPMC

### **9:00-9:30 a.m. HCC Surveillance in High Risk Liver Cancer**

Obaid Shaikh, MD  
Director, Transplant Medicine  
Professor, Division of Gastroenterology, Hepatology and Nutrition  
UPMC

### **9:30-10:00 a.m. Role of Surgical Resection and Transplantation in HCC Management**

David Geller, MD  
Director, UPMC Liver Cancer Center

### **10:00-10:30 a.m. Concurrent Session Role of Locoregional Therapies in HCC Management**

Andrew Klobuka, MD  
Department of Radiology,  
Allegheny Health Network

### **Patient Roundtable Discussion**

Brittany Morocco, MPAS, PA-C  
Senior Physician Assistant  
UPMC Liver Cancer Center

### **10:30-11:00 a.m. Medical Management of HCC**

Dulabh K Monga, MD  
Program Director, Hematology Oncology Fellowship  
Assistant Professor of Medicine  
Allegheny Health Network

### **11:00 a.m. – 11:30 a.m. Radiation Therapy for HCC**

Paul Renz, DO  
Radiation Oncology Specialist  
Allegheny Health Network

### **11:30 am to 12:00 p.m. State of the Art in Intrahepatic Cholangiocarcinoma: Diagnosis and Treatment**

Mitesh Borad, MD  
Associate Professor of Medicine  
Consultant, Division of Hematology/Oncology,  
Department of Internal Medicine,  
Mayo Clinic

### **12:00-12:30 p.m. Lunch Break**

### **12:30-1:00 p.m. Sponsor Exhibit Visits**

**1:00-1:45 p.m. Case Presentations**

**Resectable/Transplantable HCC**

Dheera Reddy, MD  
UPMC

**Non-Resectable Non-Transplantable HCC and  
Medical and Locoregional Options**

Alex Helfand, MD  
Allegheny Health Network

**Intrahepatic Cholangiocarcinoma**

Jiaxiang Liu, MD  
Allegheny Health Network

**1:45-2:00 p.m. Case Presentation Q&A**

Moderator: Dulabh K Monga, MD

**2:00 P.M. Adjournment**

**Continuing Education Credit**

In support of improving patient care, this activity has been planned and implemented by the University of Pittsburgh and Community Liver Alliance. The University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physician (CME)**

The University of Pittsburgh designates this live activity for a maximum of 4.75 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nursing (CNE)**

The maximum number of hours awarded for this Continuing Nursing Education activity is 4.75 contact hours.

**Physician Assistant (AAPA)**

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

**Faculty Disclosure**

All individuals in a position to control the content of this education activity including members of the planning committee, speakers, presenters, authors, and/or content reviewers have disclosed all relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

The following relevant financial relationships were disclosed:

Satdarshan (Paul) Singh Monga, MD

Grant/Research Support: Revolution Medicines, Inc., Aligos Therapeutics, Vicero, Inc.

Consultant: Vicero, Inc. and Aligos Therapeutics

Matesh Borad, MD

Grant/Research Support: Senhwa, Adaptimmune, Agios, Halozyme, Celgene, EMD Merck Serono, Toray, Dicerna, Taiho, Sun Biopharma, Isis Pharma, Redhill, Boston Biomed, Basilea, Incyte, Mirna, Medimmune, Bioline, Sillajen, ARIAD, PUMA, Novartis, QED, and Pieris.

Consultant: ADC Therapeutics, Exelixis, Inspyr, G1 Therapeutics, Immunovative, OncBioMune, Western Oncolytics, Lynx Group, Genentech, Merck, Huya, Astra Zeneca

Stockholder: Intercept, Spectrum Pharma, and AVEO.

No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

**Acknowledgement of Commercial Support**

*We gratefully acknowledge Exhibitors support from the following to support this activity:*

**AbbVie**

**Allegheny Health Network**

**AstraZeneca**

**BMS**

**Eisai**

**Genentch**

**Highmark**

**Merck**

**Servier**